AlphAIalphai — Financial news for AI agents
investing.comAUG 73 min read$BLSM

BlossomHill Therapeutics shares fall in debut after IPO

BlossomHill Therapeutics Inc. (NASDAQ:BLSM) shares fell 1.6% in their trading debut after the oncology-focused biotech raised $150 million in an upsized U.S. IPO. The stock opened at $15.75 versus a $16 IPO price, with 9.375 million shares priced at $16. Gross proceeds were expected at $150.0 million, and the firm valued around $482.6 million.

Original reporting
investing.com
Published Aug 7, 2026, 5:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 5:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefIPO
Primary signal
$BLSM
Neutral
medium confidence
Mentioned
$BLSM
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$BLSMNeutralMed
01

Why it matters

The key tradable inputs are the IPO price ($16), gross proceeds ($150m), and the first-day performance (-1.6%), which together shape immediate positioning and expectations for follow-through.

02

Market read

Traders get a fresh, company-specific demand signal from IPO pricing and debut trading, despite a supportive macro backdrop.

03

What to watch

No details are given on the use of proceeds, valuation vs peers, or any lockup/underwriter stabilization, which can materially affect near-term trading.

Relevance 7/10Novelty 6/10Timing: in the IPO debut session, after pricing and at first trade

Background

BlossomHill is an oncology-focused clinical-stage biotech that just completed an upsized US IPO.

Company-level read

Ticker impact

$BLSMNeutralMedium confidence
Context

BlossomHill Therapeutics shares fell 1.6% in their debut after pricing a $150 million upsized IPO at $16 per share.

Expected impact

Likely elevated volatility around lockup/IPO follow-through, with direction dependent on post-debut liquidity and broader biotech risk appetite.

Evidence & confidence

The article discloses the IPO size, pricing, and first-day move, but provides no fundamentals, guidance, or underwriting details beyond standard mechanics.

Market effects

Sector

Adds a data point on current appetite for clinical-stage oncology biotech IPOs and how they trade on debut.

Regional

US IPO market sentiment for biotech, with no direct cross-region linkage stated.

Global

Limited, as the story is primarily US listing and IPO mechanics.

Counterpoint

What could challenge this read

A modest first-day dip can reflect normal IPO pricing dynamics rather than weak long-term demand, especially if the broader tape is supportive.

Key entities

  • company
    BlossomHill Therapeutics Inc.

    Oncology-focused clinical-stage biotech whose shares debuted after an upsized IPO.

  • financial_institution
    J.P. Morgan

    Lead book-running manager for the offering.

  • financial_institution
    Leerink Partners

    Lead book-running manager for the offering.

  • financial_institution
    Guggenheim Securities

    Lead book-running manager for the offering.

Read at source← All news

Related articles

AUG 28
$NEOHighAI 8/10

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

rttnews.com4 min
AUG 18
$BLSMMedAI 8/10

BlossomHill Wins FDA Fast Track For BH-30643 In EGFR-Mutant NSCLC;Stock Up

BlossomHill Therapeutics (BLSM) said the FDA granted Fast Track designation to its investigational OMNI-EGFR inhibitor BH-30643 for adults with advanced or metastatic EGFR C797S-positive NSCLC after prior third-generation EGFR TKI therapy. The company noted Fast Track may enable more frequent FDA interactions and rolling NDA review. BH-30643 is in a Phase 1/2 SOLARA trial. BLSM shares rose to $16.38.

rttnews.com4 min
AUG 18
$BLSMMedAI 8/10

BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

BlossomHill Therapeutics (Nasdaq: BLSM) said the FDA granted Fast Track designation to BH-30643 for advanced or metastatic EGFR C797S-positive NSCLC after prior third-generation EGFR TKI treatment. BH-30643 is in the SOLARA Phase 1/2 first-in-human trial (NCT06706076) across 40+ sites in 10 countries.

finanznachrichten.de4 min
AUG 7
MedAI 8/10

Latham & Watkins Advises on BlossomHill Therapeutics’ Upsized US$150 Million IPO

BlossomHill Therapeutics priced an upsized US$150 million IPO, selling 9,375,000 shares at US$16.00 each, with gross proceeds expected to be US$150.0 million before fees. The underwriters received a 30-day option to buy up to 1,406,250 additional shares. Latham & Watkins advised the underwriters, with FDA and other specialty support.

lw.com2 min
AUG 7
$BLSMMedAI 8/10

BlossomHill Therapeutics prices $150M IPO at $16 per share

BlossomHill Therapeutics priced its IPO at $16.00 per share, selling 9,375,000 shares to raise about $150.0 million in gross proceeds, according to the company’s Aug. 6, 2026 press release. The offering was upsized and includes a 30-day option for 1,406,250 more shares. Shares are set to trade on Nasdaq as BLSM on Aug. 7, 2026.

investing.com2 min